EDGAR·FLOW

Edesa Biotech, Inc. — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 88/100
What the filing says
Edesa Biotech granted exclusive rights to paridiprubart in Japan to KYORIN Pharmaceutical for ARDS treatment. Edesa receives $12M upfront plus up to $134M in development/regulatory/sales milestones and double-digit tiered royalties on net sales. Edesa retains all rights outside Japan; Kyorin gains right of first negotiation for AKI and non-exclusive negotiation rights for other indications.
Why this rating

Deal value ($140M potential) exceeds company market cap (≈$14M) by 10x; represents major validation, cash injection, and de-risks lead asset commercialization pathway.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$2.32 ▼ 36.75%
at our read · unknown
$3.67
+10 min · unknown
$3.18 ▼ 13.35%
+30 min · unknown
$3.42 ▼ 6.81%
+1 hr · unknown
$2.87 ▼ 21.80%
+4 hrs · unknown
$2.92 ▼ 20.41%

The stock had already moved +58.09% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ EDSA · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.